A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

Investing.com -- The U.S. Food and Drug Administration launched a new program called FDA PreCheck on Thursday to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign ...

The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United ...

MAXONA Pharmaceuticals today announced that the company has submitted an Investigational New Drug (IND) Application to the ...

The trial aims to assess the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on ...

Thank you for inviting Senator Tillis’ office to participate in this listening session. Panelists were asked to address an issue impacting drug affordability and accessibility. I appreciate the ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

Obstructive sleep apnea severity measured via apnea-hypopnea index decreased among patients receiving AD109, an oral ...

The Council for Innovation Promotion (C4IP) today issued a statement taking Congress to task for supporting a bill introduced ...

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.